An experienced team of leaders working to improve brain health and patient care

Kim has 30 years of experience in accounting and finance, including 25 years in the field of healthcare diagnostic products and services. She is an operations and commercially focused leader who brings a wealth of experience in scaling organizations that bring new technology and services to market.

Prior to joining BrainScope, Kim served as the Chief Financial Officer of private equity-backed Prelude Fertility, a comprehensive fertility services company. During her time there, she led the successful integration of finance and billing operations for multiple acquisitions, establishing Prelude as the fastest growing and largest network of fertility clinics in the country.

Before Prelude, Kim spent five years as the Chief Financial Officer of Boston Heart Diagnostics, a venture-backed CVD diagnostic services start-up. At Boston Heart, Kim was responsible for establishing and scaling all aspects of the company’s financial operations, revenue cycle, commercial support, and HR functions through the successful sale of the company to Eurofins Scientific SE.

Prior to Boston Heart, Kim was the VP Finance at Ipsogen Inc., the US commercial division of French Biotech, Ipsogen S.A., a blood and breast cancer molecular diagnostic product and services company. During her time at Ipsogen, Kim established the Finance function and was responsible for all aspects of Finance and HR operations, and supported the M&A that resulted in the successful sale of the company to Qiagen.

Earlier in her career, Kim was a senior auditor at Ernst & Young LLP, held both accounting and analyst roles at American Cyanamid Company, an international agricultural, chemical, and pharmaceutical conglomerate, and had a 14-year tenure with Quest Diagnostics, a laboratory services company, where she held various roles of increasing responsibility in both Finance and Marketing.

.

Susan is an innovative and successful healthcare executive with over 30 years of diagnostics, products, and services experience. She joined BrainScope in June of 2019.

Most recently, Susan was Chief Executive Officer of private equity-backed Prelude Fertility, a comprehensive fertility services company. In just two years, Susan drove the commercial strategy, built the team, and created the largest and fastest-growing fertility services company in the country with over 28 locations in 14 states. She also completed a first of its kind deal with NYU Langone. Prelude completed a merger with Inception Fertility in April of 2019.  

Prior to BrainScope, Susan led and scaled several other successful venture/PE funded start-ups.  Leveraging her extensive history and deep knowledge of the diagnostic products and services market, she guided the strategy and execution of these companies and introduced new innovative technologies that have become standard tools in healthcare. Susan’s mission and performance driven leadership style has led to a significant positive impact on the lives of millions of patients and has helped create significant value for her shareholders.

Susan began her career at Quest Diagnostics and spent time at Oxford Health Plans and Abbott Diagnostics before taking on her first role as a CEO. In 2014, she was named an EY Entrepreneur of the Year.  Susan received an MBA from Columbia Business School and a BA in Psychology from Clemson University.  She serves on the board of directors of BreastCancer.Org and is a native New Yorker.

Leslie S. Prichep, Ph.D. is the Chief Scientific Officer of BrainScope, where she directs the Company’s scientific research and algorithm development efforts using machine learning and artificial intelligence to identify  and scientifically validate biomarkers of traumatic brain injury and concussion. She is also responsible for the scientific integrity of the product.

Dr. Prichep came to BrainScope from a significant academic tenure as a neuroscientist at NYU School of Medicine where she was the Director of the Brain Research Laboratories (BRL) and Professor of Psychiatry. The BrainScope platform has at its core, the technology she co-developed while at BRL and which were licensed from NYU.

Dr. Prichep is highly respected and known as a pioneering innovator in quantitative electrophysiology and clinically applied translational research in a number of brain-related disease states including traumatic brain injury, dementia, addiction, depression, and schizophrenia. Dr. Prichep has over 150 peer-reviewed publications, with another 55 book chapters, books, published proceedings, and monographs, holds a number of patents, and is considered one of the preeminent research scientists in the field of computerized electrophysiological. In recognition of her contribution to neurotechnology development, Dr. Prichep was elected as a Fellow of the National Academy of Inventors in 2019.

Dr. Prichep has been working with BrainScope since its inception in 2006.

Laurie Silver is the Chief Executive Office of BrainScope, a medical neurotechnology company that is improving brain health by providing objective, diagnostic insights that enable better patient care. Laurie has been with BrainScope since its inception, having previously served as both Chief Financial Officer and Chief Administrative Officer. With 30 years’ experience in strategy, operations, M&A, corporate development, finance and accounting, Laurie has been instrumental in helping shepherd the company through both its development and commercialization stages. Prior to BrainScope, Laurie served as Director of Services Mergers and Acquisitions at Symantec, where she led the integration of the customer service, consulting and education organizations upon the $13 billion merger of Symantec and Veritas. Laurie has also served as VP of Finance and Administration of a subsidiary of Sallie Mae; Director of Corporate Development and M&A at a GTCR-backed technology firm; Manager of Financial Planning and Analysis across all business units of ABC/Disney; and a Senior Auditor at Ernst & Young LLP in New York. Laurie graduated from the Stephen M. Ross School of Business at the University of Michigan and earned a CPA license from the State of New York.

Mike is an accomplished sales leader with considerable experience in bringing disruptive point-of-care technology to the market with a focus on the Golden Triangle – Emergency Medicine/Critical Care/Anesthesia Departments – and Sports Medicine. Mike comes to BrainScope with 23+ years of medical device sales and management including 19 years in the point of care ultrasound market across the US, Alaska and Hawaii.

Mike has called on over 20 different clinical specialties as a Territory Manager, Regional Business Director (Southeast, Pacific Northwest and West Regions) and Director of Musculoskeletal (United States) with FUJIFILM SonoSite and GE Healthcare. Highlights include leading three different regions to the Chairman’s Award, growing the Musculoskeletal Team from $3+ million to $25+ million, and driving adoption and implementation of products into Military Hospitals, Indian Health Care Facilities and VA Medical Centers.  

Mike has an extensive background in coaching sales and management teams to exceed their goals.  He has a bachelor’s degree in Speech Communications with a Business Minor from Penn State University. 

Susan is an innovative and successful healthcare executive with over 30 years of diagnostics, products, and services experience. She joined BrainScope in June of 2019.

Most recently, Susan was Chief Executive Officer of private equity-backed Prelude Fertility, a comprehensive fertility services company. In just two years, Susan drove the commercial strategy, built the team, and created the largest and fastest-growing fertility services company in the country with over 28 locations in 14 states. She also completed a first of its kind deal with NYU Langone. Prelude completed a merger with Inception Fertility in April of 2019.  

Prior to joining Prelude, Susan spent more than six years as President and Chief Executive Officer of Boston Heart Diagnostics, a diagnostics services start-up backed Bain Capital Ventures. During her tenure at Boston Heart, the company grew organically from $4M to just under $95M in 5 years, went from 30 to 550 employees, and tested over one million patients. Susan led the successful exit of Boston Heart in January 2015, in a deal valued at just under $200M.

Prior to Boston Heart, Susan was Chief Executive Officer at Ipsogen Inc, a molecular diagnostics company with products focused on blood and breast cancers. In less than 3 years, she built the US into the largest market within Ipsogen and along with the Founder CEO co-led the M&A that resulted in the sale of the company to Qiagen. Susan spent the earlier part of her career at Quest Diagnostics where she held various executive positions including head of marketing, corporate identity, payer contracting, and supply chain and materials management. She also spent time at Abbott Diagnostics and Oxford Health Plans (now part of United Healthcare).

Susan’s deep experience in a variety of diagnostics, provider services, and payer contracting companies have given her a unique perspective on the market. She has successfully anticipated shifting healthcare trends throughout her career and has used this to innovate and drive growth under a variety of conditions.

Susan received an MBA from Columbia University and is an EY “Entrepreneur of the Year.” (2014). She serves on the board of directors of BreastCancer.Org and is a strategic advisor to the Founders Affiliate Board of Directors of the American Heart Association.

Miles Gilburne has been active for more than 25 years as a venture capitalist, corporate strategist, and technology lawyer. He is currently a managing member of ZG Ventures, an early-stage venture capital firm focused on media, information technology, and health sciences.

Prior to forming ZG Ventures in 2000, Gilburne served for five years as Senior Vice President of Corporate Development for America Online, where he was responsible for strategic planning, corporate acquisitions, joint ventures, and alliances. He was elected to the board of directors of AOL in 1999 and, after the merger of AOL with Time Warner, continued to serve on the board of the combined company until stepping down in May 2006.

Gilburne has been an early investor in or served on the board of a wide variety of public and private companies, including media companies such as AOL, Time Warner, and Cricket Media, technology and government service companies such as Macromedia and SRA, drug development companies such as Pharmacyclics and GlycoFi, and medical device companies such as BrainScope.

Gilburne has also served as a board member of numerous non-profit organizations, including the Board of Trustees of The Shakespeare Theatre in Washington, D.C., and the Foundation for the National Institutes of Health. He received a B.A. from Princeton University and a J.D. from Harvard Law School.

Michael A. Epstein was a senior partner at Weil, Gotshal & Manges, where he practiced law for over 40 years until he retired in 2022. He is the founder and former head of Weil’s Technology & Intellectual Property Transactions practice and the co-head of the Firm’s Privacy & Cybersecurity group. Mr. Epstein also founded the Firm’s office in Silicon Valley which specializes in technology and intellectual property and served for many years on the Firm’s Management Committee and the Corporate Department Leadership group.

Mr. Epstein is the Immediate Past Chairman of the Board of Northwell Health System having served as Chair for the full four-year term (2019-2023). In addition to continuing to serve on Northwell’s Board, he is a member of the Executive Committee, Chair of the Governance and Nominating Committee, and a member of the Compensation, Finance, Legal Affairs, and Quality Committees. He is also a member of the board of Northwell’s Feinstein Institute for Medical Research. Mr. Epstein is also Immediate Past Co-Chair of the Board of the Zucker School of Medicine at Hofstra/Northwell and continues to serve on the Board.  He is Clinical Assistant Professor, Department of Medicine, at the Zucker School of Medicine where he teaches medical ethics.  In addition, Mr. Epstein is a member of the Board of the Jonas Salk Foundation and the Jewish Board of Family and Children’s Services, where he is also on the Executive Committee. Mr. Epstein is a member of the Dean’s Advisory Council for the College of Arts & Sciences at Lehigh University. He has served on advisory panels to Congress and to the National Academy of Sciences, Institute of Medicine.

Mr. Epstein is the author of the treatise Epstein on Intellectual Property, and co-author of On-line - Internet Law, International Intellectual Property, and a co-editor of Drafting License Agreements and The Corporate Counsellor’s Deskbook.  He is a founder and co-editor of Intellectual Property & Technology Law Journal and a member of the Editorial Boards of Computer Lawyer, Intellectual Property Strategist, and Cyberspace Lawyer.  He is the author of more than 60 articles on intellectual property law, has lectured worldwide on intellectual property matters, and has served as a guest lecturer at many of the leading law schools in the U.S.

James Peake was United States Secretary of Veterans Affairs from 2007 to 2009. In 2004, he retired from a 42-year United States Army career. He also served as the 40th Surgeon General of the United States Army. Peake received his Bachelor of Science degree from U.S. Military Academy at West Point in 1966 and was commissioned a second lieutenant in the U.S. Army Infantry. He served in Vietnam with the 101st Airborne Division where he was awarded the Silver Star, a Bronze Star with "V" device, and the Purple Heart with oak leaf cluster. Following his service in Vietnam, he attended Cornell University’s Weill Cornell Medical College and was awarded a medical doctorate in 1972. He is also a graduate of the United States Army War College, in 1988. He retired from the Army in 2004, as a Lieutenant General.

Dr. Peake served for four years as the United States Army Surgeon General. He also served as commander of several Army medical units. Previous key assignments include Commander, U.S. Army Medical Department Center and School and Installation Commander, Fort Sam Houston, Texas; Deputy Commander, U.S. Army Medical Command, Fort Sam Houston, Texas; Commanding General, Madigan Army Medical Center/Northwest Health Service Support Activity, Tacoma, Washington; Commanding General, 44th Medical Brigade/Corps Surgeon, XVIII Airborne Corps, Fort Bragg, North Carolina; Deputy Director, Professional Services/Chief, Consultant, Office of the Surgeon General, Falls Church, Virginia; Commander, 18th Medical Command and 121st Evacuation Hospital/Command Surgeon, Seoul, Korea; Deputy Commander for Clinical Services, Tripler Army Medical Center, Honolulu, Hawaii; Assistant Chief, Cardiothoracic Surgery, Brooke Army Medical Center, Fort Sam Houston, Texas; Staff General Surgeon/Chief, General Surgery Clinic, DeWitt Army Hospital, Fort Belvoir, Va.; and General Surgery Resident, Brooke Army Medical Center, Fort Sam Houston, Texas.

After retiring from the Army, Dr. Peake served as Executive Vice President and Chief Operating Officer of Project Hope, a non-profit international health foundation operating in more than 30 countries. While at Project HOPE he helped to orchestrate the use of civilian volunteers aboard the Navy Hospital Ship Mercy as it responded to the Tsunami disaster in Indonesia and also as part of the Hurricane Katrina response aboard the Hospital Ship Comfort.

Dr. Miller is the co-founder, chief executive officer and chairman of Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company that is focused on the development and commercialization of novel oncology and immunology therapies. He also currently serves as adjunct clinical professor of medicine (oncology) at Stanford University Medical Center. A successful serial entrepreneur, Dr. Miller founded several private and public biotech companies. These include Pharmacyclics (acquired by AbbVie), where he was co-founder and CEO and led the initial discovery and development efforts for Imbruvica® (ibrutinib); IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of Rituxan® (rituximab); Principia Biopharma, Inc.; and CellPro, Inc. Dr. Miller received the Drug Hunter Award from the University of California Drug Discovery Consortium in 2020. Dr. Miller currently serves on the Board of Bolt Biotherapeutics, Inc, a public biotechnology company and Leapfrog Bio, Inc, a private biotech company.

Cyn­thia Ringo is a Senior Part­ner of DBL Part­ners and a Man­ag­ing Part­ner of a prior fund man­aged under DBL Investors. Cynthia Ringo cur­rently sits on the board of direc­tors of The Real­Real, Urban­sit­ter, Maiyet, RubyRib­bon, Siva Power, and the Bay Area BUILD and is a mem­ber of Wom­en­Cor­po­rate­Di­rec­tors (WCD) Foun­da­tion. She also served on the board of the Forum for Women Entre­pre­neurs from 2000 to 2004, and as Chair of the Board from 2001 through 2003. Ms. Ringo was for­merly a Man­ag­ing Direc­tor of Van­tage­Point Ven­ture Part­ners from 2002 to 2008. Prior to Van­tage­Point Ven­ture Part­ners, she served as the CEO of Cop­per­com, a next-generation net­work switch­ing com­pany, from 1998 to 2001 and was the Chair­man of the Board from 2001 to 2002.

Ralph Terkowitz is an experienced executive and investor who has had a long career operating and investing in disruptive innovation. He believes that success in this domain requires out-of-the-box thinking. This mindset led to his founding or investing in operating companies such as establishing Digital Ink/WashingtonPost.com, Junglee now Amazon’s marketplace business, and Alarm.com.

Mr. Terkowitz has a keen interest in supporting research to facilitate the long-term understanding of the brain. This interest led Mr. Terkowitz to his current commitment to the Packard Center at Johns Hopkins. Mr. Terkowitz is co-chair of the Board of Governors of the Johns Hopkins Packard Center, a leading early-stage research effort that is investing in early-stage research to expand our understanding of ALS and other neurodegenerative diseases.

Mr. Terkowitz's other board experience includes American Military University, Brassring/IBM, Innovation Interactive, Truste, eCornell, and Johns Hopkins Brain Sciences Institute. He holds an A.B. in Chemistry from Cornell University and an M.S. in Chemical Physics from the University of California, Berkeley.

Gail Wilensky is an economist and a senior fellow at Project HOPE, an international health education foundation. She serves as a trustee of the Combined Benefits Fund of the United Mineworkers of America and the National Opinion Research Center, is on the Board of Regents of the Uniformed Services University of the Health Sciences (USUHS), and the Visiting Committee of Harvard Medical and Dental Schools. She recently served as president of the Defense Health Board and chaired their Health care Subcommittee, was a commissioner on the World Health Organization’s Commission on the Social Determinants of Health, and co-chaired the Dept. of Defense Task Force on the Future of Military Health Care.

She is an elected member of the Institute of Medicine and has served two terms on its governing council. She is a former chair of the board of directors of Academy Health, a former trustee of the American Heart Association, and a current or former director of numerous other non-profit organizations. She is also a director on several corporate boards. From 1990-1992, she was Administrator of the Health Care Financing Administration (now known as CMS), directing the Medicare and Medicaid programs. She also served as Deputy Assistant to President (GHW) Bush for Policy Development, advising him on health and welfare issues from 1992-1993.

From 1997-2001, she chaired the Medicare Payment Advisory Commission, which advises Congress on payment and other issues relating to Medicare, and previously chaired one of its predecessor commissions, the Physician Payment Review Commission. From 2001 to 2003, she co-chaired the President’s Task Force to Improve Health Care Delivery for Our Nation’s Veterans and in 2007, served as a Commissioner on the President’s Commission on Care for America’s Returning Wounded Warriors (Dole/Shalala Commission).

Dr. Wilensky testifies frequently before Congressional committees, serves as an advisor to members of Congress and other elected officials, speaks nationally and internationally before professional, business, and consumer groups. She received a bachelor’s degree in psychology and a Ph.D. in economics at the University of Michigan and has received several honorary degrees.

Michael (“Mike”) Kelly has been active for more than 40 years as an executive of broad management and finance, including serving as Chief Financial Officer of two Fortune 50 companies and Chief Executive Officer of International Operations. He has extensive experience with all aspects of financial operations, capital raising and financing activities, as well as investor relations.

Since 2006, Mr. Kelly has served as an active private investor, strategic advisor and Board Member to a number of organizations on strategic, financial and organizational matters. This includes firms listed on the NYSE, small venture firms, and not for profit organizations, such as INOVA Health Systems, Catholic Charities and Ingleside Retirement Community.

Prior to 2006, Mr. Kelly was Chairman and Chief Executive Officer, AOL International and Web Services. Mr. Kelly previously served as Executive Vice President and Chief Financial Officer of Time Warner. 

Mr. Kelly is a Certified Public Accountant and a graduate of Gettysburg College with a Bachelor of Arts in business administration. He currently serves on the Finance Counsel of the Archdiocese of Washington, Chairman of the Catholic Investment Trust of Washington, and Chairman of Catholic Charities Foundation of Washington. He is a member of the Board of the National Shrine of the Immaculate Conception and a Trustee Emeriti of Gettysburg College and on the Board of Cricket Media and Patrocinium Systems.